SET and chronic myelogenous leukemia, BCR-ABL1 positive: Notably, as SET-mediated PP2A inactivation is essential for the self-renewal of CML LSCs [94], re-activation of PP2A could represent a strategy to eradicate quiescent LSCs, that are typically refractory to kinase inhibitors such as imatinib [53,94,133].